

# Anti-Tumor Necrosis Factor – Alpha (TNF-a) Adjudication Guideline

**Rule Category:**  
Pharmaceutical

**Ref: No:**  
2012-PH-08

**Version Control:**  
Version No.4

**Effective Date:**  
15/07/2014

**Revision Date:**  
5/11/2024

**Approved by:**  
Daman

**Responsible:**  
Pharmacy Standards &  
Governance

**Related Adjudication  
Guidelines:**

## Table of Contents

1.	Abstract .....	3
1.1	For Members .....	3
1.2	For Medical Professionals.....	3
2.	Scope .....	3
3.	Adjudication Policy .....	4
3.1	Eligibility / Coverage Criteria .....	4
3.2	Requirements for Coverage .....	4
3.3	Non-Coverage.....	5
3.4	Payment and Coding Rules .....	5
4.	Denial Codes .....	5
5.	Appendices.....	5
5.1	References .....	5
5.2	Revision History .....	6

## 1. Abstract

### 1.1 For Members

Tumor necrosis factor (TNF-alpha) is a protein molecule that promotes the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders. These disorders are sometimes treated by using Anti-TNF alpha drugs.

Anti-tumor necrosis factor drugs are a class of drugs that have been used worldwide to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, Crohn's colitis, ankylosing spondylitis and psoriasis. These drugs can reduce inflammation and stop disease progression.

Serious side effects that have been most extensively related to TNF blockers include lymphoma, infections (sometimes severe like tuberculosis, septicemia), congestive heart failure, and injection site reactions.

### 1.2 For Medical Professionals

This Adjudication Rule highlights the coverage of Anti-Tumor Necrosis Factor Alpha (Anti TNF- $\alpha$ ) which includes Adalimumab, Infliximab, Golimumab, Certolizumab and Etanercept.

Daman covers Anti-TNF alpha when prescribed by a physician of appropriate specialty, and as per policy terms and conditions for each health insurance plan administered by Daman.

## 2. Scope

This adjudication rule highlights the coverage of Anti-TNF alpha medications, which are approved for the treatment of inflammatory conditions, according to the guidelines and international best practice.

Approval of the TNF- alpha inhibitors will be subjected upon the questionnaire and attached documents requested by Daman.

Five recommended and widely used anti-TNF alpha drugs have been developed and introduced to clinical medicine:

- Infliximab
- Adalimumab
- Golimumab
- Certolizumab
- Etanercept

All Five agents have been approved for the use in the treatment of:

Generic Name	Adalimumab	Certolizumab	Etanercept	Infliximab	Golimumab
Medical condition	Rheumatoid Arthritis	Rheumatoid Arthritis	Rheumatoid Arthritis	Rheumatoid Arthritis	Rheumatoid Arthritis
	Juvenile Idiopathic Arthritis	Juvenile Idiopathic Arthritis	Juvenile Psoriatic Arthritis	Ankylosing Spondylitis	Psoriatic Arthritis
	Psoriatic Arthritis	Psoriatic Arthritis	Psoriatic Arthritis	Psoriatic Arthritis	Ankylosing Spondylitis
	Ankylosing Spondylitis	Ankylosing Spondylitis	Plaque Psoriasis	Plaque Psoriasis	Ulcerative Colitis
	Crohn's Disease	Crohn's Disease	Pediatric Plaque Psoriasis	Crohn's Disease	
	Ulcerative Colitis	Non-Radiographic Axial Spondylarthritis	Ankylosing Spondylitis	Pediatric Crohn's disease	
	Plaque Psoriasis			Ulcerative Colitis	
	Hidradenitis Suppurativa			Pediatric Ulcerative Colitis	
	Uveitis				

### 3. Adjudication Policy

#### 3.1 Eligibility / Coverage Criteria

All the above-mentioned Anti-TNF medications (Infliximab, Adalimumab, Golimumab, Certolizumab and Etanercept) are covered for all Daman plans, except for Visitor’s plan. Coverage of these drugs for Abu Dhabi plan depends on HAAD basic drug list effective at the time of prescription.

Food and Drug administration stated that Anti-TNFα can lead to serious infections (like; TB and malignancy), and the patient should be fully aware about both serious side effects before taking the medication.

Daman will cover ANTI-TNF-α for the above-mentioned diagnosis when prescribed by a physician of appropriate specialty. They are used only after the failure of other management plans. Severity of those cases should be proven and documented properly.

Current medical references and regulatory guidelines emphasize the importance of initiating therapy with biosimilar products for patients who have not yet undergone biological treatments.

#### 3.2 Requirements for Coverage

ICD and CPT codes must be coded to the highest level of specificity.

### 3.3 Non-Coverage

Anti TNF- $\alpha$  is not covered for Visitor’s Plan. Coverage of these drugs for Abu Dhabi plan depends on HAAD basic drug list effective at the time of prescription.

### 3.4 Payment and Coding Rules

Please apply HAAD payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

## 4. Denial Codes

Code	Code Description
MNEC-003	Service is not clinically indicated based on good clinical practice
NCOV-003	Service(s) is (are) not covered
CODE-010	Activity/Diagnosis inconsistency with clinician Speciality
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnosis/activities.
CODE-014	Activity/diagnosis is inconsistent with the patient age
AUTH-001	Prior approval is required and was not obtained

## 5. Appendices

### 5.1 References

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/125057s423lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf)  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/103795s5600lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103795s5600lbl.pdf)  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/103772s5401lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103772s5401lbl.pdf)  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/125289s150lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125289s150lbl.pdf)  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/125160s275lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125160s275lbl.pdf)  
<https://www.medicines.org.uk/emc/product/3831/smipc#gref>  
[American College of Rheumatology](#)  
[The European League Against Rheumatism \(EULAR\)](#)  
[NICE guidelines](#)  
[The British Medical Journal](#)  
<http://www.basdai.com>  
<http://www.asas-group.org/clinical-instruments.php?id=01>

## 5.2 Revision History

Date	Version No.	Change(s)
15/7/2014	V1.0	Creation of Adjudication Guideline-External Instruction Template.
30/12/2021	V2.0	Criteria Update
09/08/2023	V3.0	Template updated
05/11/2024	V4.0	table of medical conditions added, denial codes, eligibility and coverage criteria update – Biosimilar use

### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed. Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.